Profil Institute Appoints Dan Bradbury, former Amylin Pharmaceutical CEO, to
Board of Directors
SAN DIEGO, Nov. 4, 2013
SAN DIEGO, Nov. 4, 2013 /PRNewswire/ --Profil® Institute for Clinical
Research, Inc., a companyproviding science-driven early phase diabetes and
obesity clinical research, announced today the appointment of Dan Bradbury,
Managing Member of BioBrit, LLC and former Amylin Pharmaceutical CEO, to its
Board of Directors. Mr. Bradbury joins Profil Institute's current Board
Directors Dr. John Amatruda, a pharmaceutical research executive and former
Senior Vice President and Head of Diabetes and Obesity at Merck Research
Laboratories; Dr. Jerrold Olefsky, Professor of Medicine at the University of
California, San Diego (UCSD) Division of Endocrinology and Metabolism and the
Associate Dean of Scientific Affairs for the UCSD School of Medicine; Dr.
Linda Morrow, Profil Institute's COO; and Dr. Marcus Hompesch, Profil
Institute's President and CEO.
"Dan Bradbury is a highly regarded and prominent leader in the global
pharmaceutical industry. We are pleased to have a person of his business
acumen and relevant experience join our Board of Directors," said Dr.
Hompesch. "With Mr. Bradbury's considerable experience in driving strategic
growth, I am certain that he will bring tremendous insight and guidance to
help further shape the company's strategic course."
"Profil Institute inhabits a unique space in today's clinical research
industry as a therapeutically focused CRO capable of providing competent and
robust guidance on all aspects of early clinical development strategy and
execution, and as an innovator of new methodologies to generate more
meaningful data for early phase studies," said Mr. Bradbury. "Profil
Institute is a growth story that I'm excited to be a part of and am pleased to
join at this time of strategic decisions for the continued expansion for the
Mr. Bradbury is a life sciences executive with over 30 years of experience
creating and implementing strategies that transform businesses and bring novel
medicines to market. He is currently Managing Member of BioBrit, LLC, a life
sciences consulting and investment firm. Prior to that, Mr. Bradbury served
as Amylin Pharmaceuticals' President, Chief Executive Officer and Director
from 2007 until its acquisition by Bristol-Myers Squibb Company in 2012.
Amylin is a biopharmaceutical company focused on metabolic diseases and based
in San Diego. During Mr. Bradbury's 18-year tenure at Amylin, the company
launched three first-in-class medicines, including the first once-a-week
therapy to treat diabetes and was listed on the Nasdaq 100. Prior to joining
Amylin, Mr. Bradbury worked in marketing and sales roles for ten years at
SmithKline Beecham Pharmaceuticals.
Mr. Bradbury serves on the Board of Directors of Corcept Therapeutics, Geron
Corporation, Illumina, Inc., BioMed Realty, Biocon Limited, Castle
Biosciences, Inc. (Private), DiaVacs (Private) and Microdermis, Inc.
(Private). He also serves on the Board of Trustees of the Keck Graduate
Institute, the Investor Growth Capital Advisory Board, and the BioMed Ventures
Advisory Committee. In addition to his Board positions, Mr. Bradbury serves on
the University of California San Diego's Rady School of Management's Advisory
Council and the University of Miami's Innovation Corporate Advisory Council.
About Profil® Institute for Clinical Research, Inc.
Profil Institute is a Center of Excellence performing early phase clinical
research of drugs and devices for diabetes and obesity and providing
scientific support for metabolic drug target profiling, clinical development
planning, publication activities and the establishment of scientific advisory
boards. The company's scientific expertise, metabolic clinical research
methodologies, and automated glucose clamp technology enable Profil Institute
to execute highly complex studies and have led Profil Institute to be a highly
regarded clinical research institute for early phase metabolic drug studies.
Profil Institute has been involved with every clinically relevant drug class
in diabetes and in more than 200 clinical studies since the company's
inception in 2004. For more information, visit www.profilinstitute.com.
SOURCE Profil Institute for Clinical Research
Contact: Abby Devine, Corporate Communications,
Press spacebar to pause and continue. Press esc to stop.